WM and Lymphoma Report: ASCO/EHA 2020
Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma

Released: August 31, 2020

Expiration: August 30, 2021

John N. Allan
John N. Allan, MD
Jennifer R. Brown
Jennifer R. Brown, MD, PhD

Activity

Progress
1
Course Completed

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in Waldenström macroglobulinemia, mantle cell lymphoma, Hodgkin lymphoma, and DLBCL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies include:

  • ASPEN: Zanubrutinib vs ibrutinib in WM
  • OASIS: Ibrutinib, venetoclax, and obinutuzumab in MCL
  • GHSG HD17: PET-guided therapy in HL
  • KEYNOTE-024: Pembrolizumab vs brentuximab in HL
  • ALEXANDER: AUTO3 in DLBCL

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program: https://www.clinicaloptions.com/oncology/conference-coverage/global-asco-eha-2020